MX2023006157A - Mediadores lipidicos proresolutivos especializados para el tratamiento del pcos. - Google Patents

Mediadores lipidicos proresolutivos especializados para el tratamiento del pcos.

Info

Publication number
MX2023006157A
MX2023006157A MX2023006157A MX2023006157A MX2023006157A MX 2023006157 A MX2023006157 A MX 2023006157A MX 2023006157 A MX2023006157 A MX 2023006157A MX 2023006157 A MX2023006157 A MX 2023006157A MX 2023006157 A MX2023006157 A MX 2023006157A
Authority
MX
Mexico
Prior art keywords
lipid mediators
resolving lipid
specialized pro
pcos
treating pcos
Prior art date
Application number
MX2023006157A
Other languages
English (en)
Inventor
Pedro Antonio Regidor
José Miguel Rizo
Rocío Gutierrez
Original Assignee
Chemo Res S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Res S L filed Critical Chemo Res S L
Publication of MX2023006157A publication Critical patent/MX2023006157A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a un tratamiento del síndrome de ovario poliquístico (PCOS) mediante el uso de mediadores lipídicos proresolutivos especializados (SPM) o sus precursores activos, opcionalmente en combinación con un fármaco antiinflamatorio no esteroideo.
MX2023006157A 2020-12-04 2021-12-03 Mediadores lipidicos proresolutivos especializados para el tratamiento del pcos. MX2023006157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20383064 2020-12-04
PCT/EP2021/084195 WO2022117828A1 (en) 2020-12-04 2021-12-03 Specialized pro-resolving lipid mediators for treating pcos

Publications (1)

Publication Number Publication Date
MX2023006157A true MX2023006157A (es) 2023-06-08

Family

ID=73834419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006157A MX2023006157A (es) 2020-12-04 2021-12-03 Mediadores lipidicos proresolutivos especializados para el tratamiento del pcos.

Country Status (3)

Country Link
EP (1) EP4255412A1 (es)
MX (1) MX2023006157A (es)
WO (1) WO2022117828A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080273A1 (en) 2010-12-16 2012-06-21 Iasomai Ab N- acetyl - l - cysteine for treatment of polycystic ovary syndrome
CN116173001A (zh) 2012-05-10 2023-05-30 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油

Also Published As

Publication number Publication date
EP4255412A1 (en) 2023-10-11
WO2022117828A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
ECSP21033236A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
BR112021022832A2 (pt) Pirrois tricíclicos condensados como moduladores da alfa-1 antitripsina
PA8680701A1 (es) Derivados de oxindol
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
CY1114981T1 (el) Προφαρμακα ντολουτεγκραβιρης
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
DOP2012000151A (es) Nuevos compuestos triciclicos
MX2021006695A (es) Moduladores de trex1.
EA202190581A1 (ru) Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a
AR122505A1 (es) Procesos para preparar un inhibidor de jak1
BR112019005886A2 (pt) tratamento com água de material lipídico
MX2021015673A (es) Alteracion de biopelicula.
MX2023006157A (es) Mediadores lipidicos proresolutivos especializados para el tratamiento del pcos.
CL2021002373A1 (es) Fármaco y método para tratar o prevenir las complicaciones de la diabetes utilizando dicho fármaco
ECSP23088732A (es) Moduladores de trex1
BR112022012283A2 (pt) Combinações
PH12020550222A1 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
CL2021000892A1 (es) Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica
MX2022003816A (es) Compuestos antibacterianos.
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
BR112022003126A2 (pt) Conjugado terapêutico
MX2020008504A (es) Agentes terapeuticos para tratar el sindrome de piernas inquietas.
BR112021012859A2 (pt) Minociclina para o tratamento da síndrome de pitt-hopkins
EA202191335A1 (ru) Соединения и композиции для лечения состояний, ассоциированных с активностью nlrp